Ukoniq

Chemical Nameumbralisib
Dosage FormTablet (oral; 200 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyTG Therapeutics, Inc.
Approval Year2021

Indication

  • For the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen
  • For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy
Last updated on 2/24/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ukoniq (umbralisib) Prescribing Information2021TG Therapeutics, Inc. Edison, NJ